Treace Medical Concepts (NASDAQ:TMCI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Treace Medical Concepts (NASDAQ:TMCI) from a sell rating to a hold rating in a report issued on Monday.

Several other research analysts have also recently commented on TMCI. Stifel Nicolaus decreased their target price on shares of Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, January 7th. UBS Group decreased their price objective on shares of Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating for the company in a research note on Friday, November 7th. JPMorgan Chase & Co. reissued an “underweight” rating and set a $5.00 target price (down from $8.00) on shares of Treace Medical Concepts in a research note on Friday, November 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Wednesday, January 21st. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Treace Medical Concepts in a research report on Friday, November 7th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Treace Medical Concepts presently has a consensus rating of “Reduce” and a consensus target price of $4.21.

Treace Medical Concepts Stock Performance

TMCI opened at $2.04 on Monday. The firm has a market cap of $129.99 million, a PE ratio of -2.55 and a beta of 0.74. The company has a quick ratio of 2.36, a current ratio of 3.37 and a debt-to-equity ratio of 0.60. The business has a fifty day simple moving average of $2.37 and a 200-day simple moving average of $4.47. Treace Medical Concepts has a fifty-two week low of $1.81 and a fifty-two week high of $10.03.

Institutional Trading of Treace Medical Concepts

Several large investors have recently added to or reduced their stakes in TMCI. Graham Capital Management L.P. acquired a new stake in shares of Treace Medical Concepts in the 4th quarter valued at $27,000. Osaic Holdings Inc. lifted its position in shares of Treace Medical Concepts by 328.3% in the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after buying an additional 3,674 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of Treace Medical Concepts during the 4th quarter worth about $33,000. Balance Wealth LLC bought a new position in shares of Treace Medical Concepts in the 4th quarter valued at approximately $37,000. Finally, AXQ Capital LP bought a new position in shares of Treace Medical Concepts in the 4th quarter valued at approximately $42,000. 84.08% of the stock is owned by institutional investors.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.